A submission for European marketing authorization for filgotinib in ulcerative colitis (UC) has been validated, and will be reviewed by the European Medicines Agency.
US biotech major Gilead Sciences (Nasdaq: GILD) and its co-developer, Belgium-based Galapagos (Euronext: GLPG), are developing the oral JAK-1 blocker in multiple indications.
The submission in UC is based on results from the Phase IIb/III SELECTION trial, which achieved all primary endpoints, inducing clinical remission at week 10, at the higher 200mg dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze